We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Galectin Therapeutics Inc | NASDAQ:GALT | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.01 | -0.28% | 3.50 | 3.46 | 3.54 | 3.62 | 3.46 | 3.55 | 107,319 | 21:00:02 |
1. Name and Address of Reporting Person * 10X Fund, L.P. | 2. Issuer Name and Ticker or Trading Symbol GALECTIN THERAPEUTICS INC [ GALT ] |
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director __X__ 10% Owner _____ Officer (give title below) _____ Other (specify below) |
|
3. Date of Earliest Transaction
(MM/DD/YYYY)
|
|
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
___ Form filed by One Reporting Person
_ X _ Form filed by More than One Reporting Person |
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned |
||||||||||
1.Title of Security (Instr. 3) |
2. Trans. Date | 2A. Deemed Execution Date, if any |
3. Trans. Code (Instr. 8) |
4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) |
5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) |
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | |||
Code | V | Amount | (A) or (D) | Price | ||||||
Common Stock | 8/2/2019 | J | 38690 | D | (3) | 6402790 | D (1) | |||
Common Stock | 10/10/2019 | S(2) | 17000 | D | $3.725 | 6385790 | D (1) |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) |
|||||||||||||||
1. Title of Derivate Security (Instr. 3) |
2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any |
4. Trans. Code (Instr. 8) |
5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) |
6. Date Exercisable and Expiration Date |
7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) |
8. Price of Derivative Security (Instr. 5) |
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | ||||
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Reporting Owners |
|||||
Reporting Owner Name / Address |
|
||||
Director | 10% Owner | Officer | Other | ||
10X Fund, L.P. 545 DUTCH VALLEY ROAD, N.E., SUITE A ATLANTA,, GA 30324 |
X | ||||
10X Capital Management, LLC 545 DUTCH VALLEY ROAD, N.E., SUITE A ATLANTA,, GA 30324 |
General partner | ||||
CZIRR JAMES C 545 DUTCH VALLEY ROAD, N.E., SUITE A ATLANTA,, GA 30324 |
Managing Member of GP |
Signatures |
||
/s/ James C. Czirr, as Managing Member of the General Partner for 10X Fund, LP | 10/15/2019 | |
**Signature of Reporting Person | Date | |
/s/ James C. Czirr, as Managing Member of 10X Capital Management, LLC | 10/15/2019 | |
**Signature of Reporting Person | Date | |
/s/ James C. Czirr, Individually | 10/15/2019 | |
**Signature of Reporting Person | Date |
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | |
* | If the form is filed by more than one reporting person, see Instruction 4(b)(v). |
** | Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). |
Note: | File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. |
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. |
1 Year Galectin Therapeutics Chart |
1 Month Galectin Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions